Monte Rosa Therapeutics Inc (GLUE)
$13.98
$-0.40
(-2.78%)
As on 04-Sep-2026 13:36EDT
Market cap
$1,141 Mln
Revenue (TTM)
$29 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
51.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.2
-
Face value
--
-
Shares outstanding
85,313,401
5 Years Aggregate
CFO
$-224.86 Mln
EBITDA
$-357.23 Mln
Net Profit
$-356.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc (GLUE)
| -10.8 | -9.1 | -20.5 | 179.6 | 31.1 | -19.8 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc (GLUE)
| 125.9 | 22.6 | -25.8 | -62.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Monte Rosa Therapeutics Inc (GLUE)
|
14.0 | 1,141.5 | 28.7 | -161.1 | -570.8 | -44.7 | -- | 2.5 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The... company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. Read more
-
President, CEO & Director
Dr. Markus Warmuth M.D.
-
President, CEO & Director
Dr. Markus Warmuth M.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Monte Rosa Therapeutics Inc (GLUE)
What is the current share price of Monte Rosa Therapeutics Inc (GLUE) Today?
The share price of Monte Rosa Therapeutics Inc (GLUE) is $13.98 (NASDAQ) as of 04-Sep-2026 13:36 EDT. Monte Rosa Therapeutics Inc (GLUE) has given a return of 31.13% in the last 3 years.
What is the current PB & PE ratio of Monte Rosa Therapeutics Inc (GLUE)?
Since, TTM earnings of Monte Rosa Therapeutics Inc (GLUE) is negative, P/E ratio is not available.
The P/B ratio of Monte Rosa Therapeutics Inc (GLUE) is 2.52 times as on 28-Aug-2026, a 51 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-26.61 |
4.41 |
2024 |
-5.86 |
1.91 |
2023 |
-2.38 |
1.79 |
2022 |
-3.43 |
1.37 |
2021 |
-12.70 |
2.70 |
What is the 52 Week High and Low of Monte Rosa Therapeutics Inc (GLUE)?
The 52-week high and low of Monte Rosa Therapeutics Inc (GLUE) are Rs 25.77 and Rs 4.79 as of 05-Sep-2026.
What is the market cap of Monte Rosa Therapeutics Inc (GLUE)?
Monte Rosa Therapeutics Inc (GLUE) has a market capitalisation of $ 1,141 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Monte Rosa Therapeutics Inc (GLUE)?
Before investing in Monte Rosa Therapeutics Inc (GLUE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.